MINI CV
- 2015 : Master 1 Université Toulouse III Paul Sabatier
Laboratoire génétique des troubles de la réfraction et des anomalies du développement de l’œil (Pr CALVAS)
EA 4555 – CPTP – INSERM Toulouse
- 2021 : Thèse d’exercice docteur en Médecine Université Toulouse III Paul Sabatier
Traitement post-opératoire des patients porteurs d’une maladie de Crohn opérés en échec d’une première ligne d’anti TNFα
- 2022 : Master 2 Santé Digestive et Nutrition Toulouse III Paul Sabatier mention très bien
Institut de Recherche en Santé Digestive (Nathalie VERGNOLLE)
UMR 1220 – INSERM Toulouse
- 2017 : Master of Science Year 1, Toulouse III Paul Sabatier University
Genetic laboratory : refractive errors and abnormalities of eye’s development (Pr CALVAS)
EA 4555 – CPTP – INSERM Toulouse
- 2021 : M.D. - Toulouse III Paul Sabatier University
Prevention of Post-Operative Recurrence of Crohn’s Disease among Patients with Prior Anti-TNFα Failure
- 2022 : Master of Science Year 2, Digestive Health and Nutrition Toulouse III Paul Sabatier University
Digestive Health Research Institute (Nathalie VERGNOLLE)
UMR 1220 – INSERM Toulouse
Laboratoire génétique des troubles de la réfraction et des anomalies du développement de l’œil (Pr CALVAS)
EA 4555 – CPTP – INSERM Toulouse
- 2021 : Thèse d’exercice docteur en Médecine Université Toulouse III Paul Sabatier
Traitement post-opératoire des patients porteurs d’une maladie de Crohn opérés en échec d’une première ligne d’anti TNFα
- 2022 : Master 2 Santé Digestive et Nutrition Toulouse III Paul Sabatier mention très bien
Institut de Recherche en Santé Digestive (Nathalie VERGNOLLE)
UMR 1220 – INSERM Toulouse
- 2017 : Master of Science Year 1, Toulouse III Paul Sabatier University
Genetic laboratory : refractive errors and abnormalities of eye’s development (Pr CALVAS)
EA 4555 – CPTP – INSERM Toulouse
- 2021 : M.D. - Toulouse III Paul Sabatier University
Prevention of Post-Operative Recurrence of Crohn’s Disease among Patients with Prior Anti-TNFα Failure
- 2022 : Master of Science Year 2, Digestive Health and Nutrition Toulouse III Paul Sabatier University
Digestive Health Research Institute (Nathalie VERGNOLLE)
UMR 1220 – INSERM Toulouse
Projets de recherche / research projects :
Rôle des protéases épithéliales sur la dysbiose du biofilm intestinal au cours des Maladies Inflammatoires Chroniques de l'Intestin
Epithelial proteases impact on gut dysbiosis in Inflammatory Bowel Diseases
Il a été mis en évidence que l’épithélium intestinal sécrète de la thrombine sous forme active et que cette protéase est physiologiquement nécessaire au maintien d’une barrière contre les biofilms bactériens invasifs (Motta et al. Nature Comm 2019). La maladie de Crohn est associée à une augmentation de la production de thrombine à la surface de la muqueuse intestinale à l’origine de lésions inflammatoires dues à l’activation de récepteurs activés par les protéases (PAR ; Motta et al. JCC 2021).
Le but de notre étude est d’analyser l’impact de cette surexposition du biofilm muqueux à de la thrombine épithéliale au cours de la maladie de Crohn sur la composition, la structure physique, la capacité de dispersion du biofilm et ses interactions avec l’épithélium sous-jacent. Des approches thérapeutiques visant à moduler l’activité protéolytique épithéliale seront testées afin de restaurer les propriétés du biofilm intestinal.
The intestinal epithelium has been shown to secrete thrombin in an active form. This protease is physiologically necessary to maintain a barrier against invasive bacterial biofilms (Motta et al. Nature Comm 2019). Crohn's disease is associated with an increase production of thrombin on the surface of the intestinal mucosa causing inflammatory lesions due to the activation of protease-activated receptors (PAR; Motta et al. JCC 2021).
The aim of our study is to analyze the impact of this overexposure of the mucosal biofilm to epithelial thrombin during Crohn's disease on the composition, the physical structure, the dispersal capacity of the biofilm and its interactions with the underlying epithelium. Therapeutic approaches aiming to modulate epithelial proteolytic activity will be tested in order to restore the properties of the intestinal biofilm.
Epithelial proteases impact on gut dysbiosis in Inflammatory Bowel Diseases
Il a été mis en évidence que l’épithélium intestinal sécrète de la thrombine sous forme active et que cette protéase est physiologiquement nécessaire au maintien d’une barrière contre les biofilms bactériens invasifs (Motta et al. Nature Comm 2019). La maladie de Crohn est associée à une augmentation de la production de thrombine à la surface de la muqueuse intestinale à l’origine de lésions inflammatoires dues à l’activation de récepteurs activés par les protéases (PAR ; Motta et al. JCC 2021).
Le but de notre étude est d’analyser l’impact de cette surexposition du biofilm muqueux à de la thrombine épithéliale au cours de la maladie de Crohn sur la composition, la structure physique, la capacité de dispersion du biofilm et ses interactions avec l’épithélium sous-jacent. Des approches thérapeutiques visant à moduler l’activité protéolytique épithéliale seront testées afin de restaurer les propriétés du biofilm intestinal.
The intestinal epithelium has been shown to secrete thrombin in an active form. This protease is physiologically necessary to maintain a barrier against invasive bacterial biofilms (Motta et al. Nature Comm 2019). Crohn's disease is associated with an increase production of thrombin on the surface of the intestinal mucosa causing inflammatory lesions due to the activation of protease-activated receptors (PAR; Motta et al. JCC 2021).
The aim of our study is to analyze the impact of this overexposure of the mucosal biofilm to epithelial thrombin during Crohn's disease on the composition, the physical structure, the dispersal capacity of the biofilm and its interactions with the underlying epithelium. Therapeutic approaches aiming to modulate epithelial proteolytic activity will be tested in order to restore the properties of the intestinal biofilm.
Modèles animaux et cellulaires / ANIMAL AND CELLULAR MODELS
Modèle d’étude :
- Modèle murin maladie inflammatoire chronique de l'intestin (Murine model of chronic inflammatory bowel disease)
- Modèle de biofilm bactérien à partir de biopsies et de selles d’origine humaine (Microbiology : Study of bacterials strains and polymicrobial biofilms from gut (biocollection of human microbiota from biopsies and stools)
Techniques et méthodes / TECHNICS AND METHODS
- Biologie moléculaire (PCR, RT-(q)PCR), Extraction ARN/ADNg (Molecular biology (PCR, RT-(q)PCR), RNA and gDNA extraction)
- Protéines : extraction et purification (Protein extraction and purification)
- Marquages immunohistologiques (Immunostaining)
PUBLICATIONS
1. Le Cosquer, G.; Maulat, C.; Bournet, B.; Cordelier, P.; Buscail, E.; Buscail, L. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach.
Cancers 2023, 15, 761, doi:10.3390/cancers15030761.
2. Bozon, A.; Nancey, S.; Serrero, M.; Caillo, L.; Gilletta, C.; Benezech, A.; Combes, R.; Danan, G.; Akouete, S.; Pages, L.; et al. Risk of Infection in Elderly Patients with Inflammatory Bowel Disease under Biologics: A Prospective, Multicenter, Observational, One-Year Follow-up Comparative Study. Clin Res Hepatol Gastroenterol 2023, 47, 102107, doi:10.1016/j.clinre.2023.102107.
3. Le Cosquer, G.; Zadro, C.; Gilletta, C. A Rare Pregnancy-Related Complication of Crohn’s Disease: Diagnosis and Treatment. Gastroenterology 2022, 163, 586–587, doi:10.1053/j.gastro.2022.05.018.
4. Le Cosquer, G.; Célérier, B.; Laharie, D. A Rare Cause of Colonic Obstruction in Inflammatory Bowel Disease. Official journal of the American College of Gastroenterology | ACG 2022, 10.14309/ajg.0000000000002116, doi:10.14309/ajg.0000000000002116.
5. Le Cosquer, G.; Grangeon, L.; Rivière, P.; Berger, A.; Zerbib, F.; Laharie, D.; Poullenot, F. A Single Dedicated Vaccination Visit Improves Vaccination Coverage of Patients with Inflammatory Bowel Disease. Therap Adv Gastroenterol 2022, 15, 17562848221082880, doi:10.1177/17562848221082879.
6. Le Cosquer, G.; Brunac, A.C.; Peron, J.M. An Unusual Case of Budd-Chiari Syndrome: Diagnosis and Treatment. Gastroenterology 2022, S0016-5085(22)00115-9, doi:10.1053/j.gastro.2022.01.049.
7. Le Cosquer, G.; Buscail, E.; Gilletta, C.; Deraison, C.; Duffas, J.-P.; Bournet, B.; Tuyeras, G.; Vergnolle, N.; Buscail, L. Incidence and Risk Factors of Cancer in the Anal Transitional Zone and Ileal Pouch Following Surgery for Ulcerative Colitis and Familial Adenomatous Polyposis. Cancers (Basel) 2022, 14, 530, doi:10.3390/cancers14030530.
8. Le Cosquer, G.; Altwegg, R.; Rivière, P.; Bournet, B.; Boivineau, L.; Poullenot, F.; Bozon, A.; Buscail, L.; Laharie, D.; Gilletta, C. Prevention of Post-Operative Recurrence of Crohn’s Disease among Patients with Prior Anti-TNFα Failure: A Retrospective Multicenter Study. Digestive and Liver Disease 2022, S159086582200696X, doi:10.1016/j.dld.2022.09.004.
9. Le Cosquer, G.; Barranca, A.; Lapotre, L.; Casassa, E.; Chaput, B.; Ciron, J.; Buscail, L.; Paul, C.; Gilletta, C. Severe Vulvar and Perianal Crohn’s Disease: A Case Report and Review of the Literature. Case Rep Dermatol 2022, 14, 24–30, doi:10.1159/000522033.
10. Le Cosquer, G.; Ribes, D.; Faguer, S.; Jeune, M.; Alric, L.; Bournet, B.; Buscail, L. Long-Term Follow-Up and Immunomonitoring of Relapsing Type 1 Autoimmune Pancreatitis Treated With Rituximab. Pancreas 2022, 51, 452–462, doi:10.1097/MPA.0000000000002048.
11. Buscail, E.; Le Cosquer, G.; Gross, F.; Lebrin, M.; Bugarel, L.; Deraison, C.; Vergnolle, N.; Bournet, B.; Gilletta, C.; Buscail, L. Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn’s Disease: Rationale, Clinical Results and Perspectives. Int J Mol Sci 2021, 22, 9967, doi:10.3390/ijms22189967.
Cancers 2023, 15, 761, doi:10.3390/cancers15030761.
2. Bozon, A.; Nancey, S.; Serrero, M.; Caillo, L.; Gilletta, C.; Benezech, A.; Combes, R.; Danan, G.; Akouete, S.; Pages, L.; et al. Risk of Infection in Elderly Patients with Inflammatory Bowel Disease under Biologics: A Prospective, Multicenter, Observational, One-Year Follow-up Comparative Study. Clin Res Hepatol Gastroenterol 2023, 47, 102107, doi:10.1016/j.clinre.2023.102107.
3. Le Cosquer, G.; Zadro, C.; Gilletta, C. A Rare Pregnancy-Related Complication of Crohn’s Disease: Diagnosis and Treatment. Gastroenterology 2022, 163, 586–587, doi:10.1053/j.gastro.2022.05.018.
4. Le Cosquer, G.; Célérier, B.; Laharie, D. A Rare Cause of Colonic Obstruction in Inflammatory Bowel Disease. Official journal of the American College of Gastroenterology | ACG 2022, 10.14309/ajg.0000000000002116, doi:10.14309/ajg.0000000000002116.
5. Le Cosquer, G.; Grangeon, L.; Rivière, P.; Berger, A.; Zerbib, F.; Laharie, D.; Poullenot, F. A Single Dedicated Vaccination Visit Improves Vaccination Coverage of Patients with Inflammatory Bowel Disease. Therap Adv Gastroenterol 2022, 15, 17562848221082880, doi:10.1177/17562848221082879.
6. Le Cosquer, G.; Brunac, A.C.; Peron, J.M. An Unusual Case of Budd-Chiari Syndrome: Diagnosis and Treatment. Gastroenterology 2022, S0016-5085(22)00115-9, doi:10.1053/j.gastro.2022.01.049.
7. Le Cosquer, G.; Buscail, E.; Gilletta, C.; Deraison, C.; Duffas, J.-P.; Bournet, B.; Tuyeras, G.; Vergnolle, N.; Buscail, L. Incidence and Risk Factors of Cancer in the Anal Transitional Zone and Ileal Pouch Following Surgery for Ulcerative Colitis and Familial Adenomatous Polyposis. Cancers (Basel) 2022, 14, 530, doi:10.3390/cancers14030530.
8. Le Cosquer, G.; Altwegg, R.; Rivière, P.; Bournet, B.; Boivineau, L.; Poullenot, F.; Bozon, A.; Buscail, L.; Laharie, D.; Gilletta, C. Prevention of Post-Operative Recurrence of Crohn’s Disease among Patients with Prior Anti-TNFα Failure: A Retrospective Multicenter Study. Digestive and Liver Disease 2022, S159086582200696X, doi:10.1016/j.dld.2022.09.004.
9. Le Cosquer, G.; Barranca, A.; Lapotre, L.; Casassa, E.; Chaput, B.; Ciron, J.; Buscail, L.; Paul, C.; Gilletta, C. Severe Vulvar and Perianal Crohn’s Disease: A Case Report and Review of the Literature. Case Rep Dermatol 2022, 14, 24–30, doi:10.1159/000522033.
10. Le Cosquer, G.; Ribes, D.; Faguer, S.; Jeune, M.; Alric, L.; Bournet, B.; Buscail, L. Long-Term Follow-Up and Immunomonitoring of Relapsing Type 1 Autoimmune Pancreatitis Treated With Rituximab. Pancreas 2022, 51, 452–462, doi:10.1097/MPA.0000000000002048.
11. Buscail, E.; Le Cosquer, G.; Gross, F.; Lebrin, M.; Bugarel, L.; Deraison, C.; Vergnolle, N.; Bournet, B.; Gilletta, C.; Buscail, L. Adipose-Derived Stem Cells in the Treatment of Perianal Fistulas in Crohn’s Disease: Rationale, Clinical Results and Perspectives. Int J Mol Sci 2021, 22, 9967, doi:10.3390/ijms22189967.